DOP2018000058A - Inhibidores de ezh2 - Google Patents

Inhibidores de ezh2

Info

Publication number
DOP2018000058A
DOP2018000058A DO2018000058A DO2018000058A DOP2018000058A DO P2018000058 A DOP2018000058 A DO P2018000058A DO 2018000058 A DO2018000058 A DO 2018000058A DO 2018000058 A DO2018000058 A DO 2018000058A DO P2018000058 A DOP2018000058 A DO P2018000058A
Authority
DO
Dominican Republic
Prior art keywords
compounds
ezh2 inhibitors
ezh2
zeste
hematological
Prior art date
Application number
DO2018000058A
Other languages
English (en)
Inventor
Filadelfa Del Prado Miriam
Yee Mai Yip Yvonne
Margaret Mader Mary
Yu Kuo-Long
John Rodriguez Michael
Dominguez Esteban
Guo Deqi
Enrico Richett Michael
Hannah Nguyen Anh-Quan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2018000058A publication Critical patent/DOP2018000058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a compuestos que inhiben la actividad de la histona lisina metiltransferasa, Potenciador del Homólogo Zeste 2 (EZH2, por sus siglas en inglés), composiciones farmacéuticas que comprenden los compuestos, y métodos para usar los compuestos para tratar cáncer, tales como tumores hematológicos y sólidos.
DO2018000058A 2015-08-27 2018-02-22 Inhibidores de ezh2 DOP2018000058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382433 2015-08-27
EP15382615 2015-12-11

Publications (1)

Publication Number Publication Date
DOP2018000058A true DOP2018000058A (es) 2018-03-30

Family

ID=56801893

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000058A DOP2018000058A (es) 2015-08-27 2018-02-22 Inhibidores de ezh2

Country Status (31)

Country Link
US (1) US9718838B2 (es)
EP (1) EP3341379B1 (es)
JP (1) JP6704040B2 (es)
KR (1) KR20180030704A (es)
CN (1) CN107922434B (es)
AU (1) AU2016313541A1 (es)
BR (1) BR112018003108A2 (es)
CA (1) CA2994428A1 (es)
CO (1) CO2018002033A2 (es)
CR (1) CR20180104A (es)
CY (1) CY1122364T1 (es)
DK (1) DK3341379T3 (es)
DO (1) DOP2018000058A (es)
EC (1) ECSP18014798A (es)
ES (1) ES2756603T3 (es)
HR (1) HRP20192101T1 (es)
HU (1) HUE047630T2 (es)
IL (1) IL257061A (es)
LT (1) LT3341379T (es)
MD (1) MD3341379T2 (es)
ME (1) ME03650B (es)
MX (1) MX2018002484A (es)
PE (1) PE20181025A1 (es)
PH (1) PH12018500423A1 (es)
PL (1) PL3341379T3 (es)
PT (1) PT3341379T (es)
RS (1) RS59615B1 (es)
SI (1) SI3341379T1 (es)
TN (1) TN2018000058A1 (es)
TW (1) TW201718598A (es)
WO (1) WO2017035060A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL198975B1 (pl) * 1999-04-22 2008-08-29 Biogen Idec Inc Zastosowanie kompozycji zawierającej homolog przeciwciała, który jest antagonistą interakcji między integryną niosącą podjednostkę alfa 4 a jej ligandem
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
CA3023157A1 (en) * 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
JP2019527037A (ja) * 2016-06-08 2019-09-26 ジェネンテック， インコーポレイテッド がんのための診断及び治療方法
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
JP7025556B2 (ja) 2018-01-31 2022-02-24 ミラティ セラピューティクス， インコーポレイテッド Ｐｒｃ２阻害剤
CN111601791B (zh) * 2018-04-24 2022-10-04 上海海雁医药科技有限公司 Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119198A1 (en) * 2000-07-24 2002-08-29 Ping Gao Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
JP2004524277A (ja) * 2000-10-20 2004-08-12 ブリストル−マイヤーズ スクイブ ファーマ カンパニー アシルセミカルバジド及びサイクリン依存性キナーゼ（ｃｄｋ）阻害剤としてのその使用
CN100441176C (zh) * 2001-09-24 2008-12-10 杰西·L·S·奥 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物
JP2006521794A (ja) 2003-02-14 2006-09-28 スミスクライン・ビーチャム・コーポレイション Ｋｓｐ発現と相関関係にある示差発現核酸
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
CN103261890B (zh) 2010-09-10 2016-04-06 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
ES2607064T3 (es) 2010-12-01 2017-03-29 Glaxosmithkline Llc Indoles
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
EP2755962B1 (en) 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
RU2014117632A (ru) 2011-09-30 2015-11-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы лечения злокачественной опухоли
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013067296A1 (en) 2011-11-04 2013-05-10 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Method of treatment
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN110420327B (zh) 2012-03-12 2022-05-03 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
US20150108176A1 (en) 2012-04-12 2015-04-23 E I Du Pont De Nemours And Company Can tap
ES2925312T3 (es) 2012-04-13 2022-10-14 Epizyme Inc Terapia combinada para el tratamiento del cáncer
PT2836491T (pt) 2012-04-13 2017-02-08 Eisai R&D Man Co Ltd Forma salina de um inibidor da histona metiltransferase humana ezh2
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
EP2854811A1 (en) * 2012-05-31 2015-04-08 Amgen Inc. Use of amg 900 for the treatment of cancer
WO2014049488A1 (en) 2012-09-28 2014-04-03 Pfizer Inc. Benzamide and heterobenzamide compounds
SG11201502803VA (en) 2012-10-15 2015-05-28 Epizyme Inc Substituted benzene compounds
CA3177498A1 (en) 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer
EP2931707A4 (en) 2012-12-13 2016-07-20 Glaxosmithkline Llc AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
AU2013361060B2 (en) 2012-12-21 2018-04-19 Epizyme, Inc. 1,4-pyridone compounds
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
RS56207B1 (sr) 2013-02-11 2017-11-30 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
NZ630205A (en) * 2013-04-30 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Enhancer of zeste homolog 2 inhibitors
RU2016104044A (ru) 2013-07-10 2017-08-15 Глэксосмитклайн Интеллекчуал Проперти (Nо.2) Лимитед Ингибиторы усилителя zeste гомолога 2
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2015058125A1 (en) 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015104677A1 (en) 2014-01-10 2015-07-16 Piramal Enterprises Limited Heterocyclic compounds as ezh2 inhibitors
EP3121175B1 (en) 2014-03-17 2019-12-04 Daiichi Sankyo Company, Limited 1,3-benzodioxole derivatives as ezh1 and/or ezh2 inhibitors
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
US10166238B2 (en) 2014-06-17 2019-01-01 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
RS58632B1 (sr) 2014-06-17 2019-05-31 Pfizer Supstituisana jedinjenja dihidroizohinolinona
CA2952285A1 (en) 2014-06-19 2015-12-23 Memorial Sloan-Kettering Cancer Center Biomarkers for response to ezh2 inhibitors
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
US20170334891A1 (en) 2014-10-28 2017-11-23 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
WO2016130396A1 (en) 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2016140501A1 (en) 2015-03-04 2016-09-09 Kainos Medicine, Inc. Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑

Also Published As

Publication number Publication date
HUE047630T2 (hu) 2021-12-28
CY1122364T1 (el) 2021-01-27
US20170066780A1 (en) 2017-03-09
EP3341379B1 (en) 2019-10-09
JP6704040B2 (ja) 2020-06-03
CN107922434A (zh) 2018-04-17
PT3341379T (pt) 2019-12-16
PH12018500423A1 (en) 2018-08-29
JP2018530527A (ja) 2018-10-18
MX2018002484A (es) 2018-06-15
US9718838B2 (en) 2017-08-01
RS59615B1 (sr) 2020-01-31
AU2016313541A1 (en) 2018-02-15
BR112018003108A2 (pt) 2018-09-25
LT3341379T (lt) 2019-12-10
EP3341379A1 (en) 2018-07-04
PE20181025A1 (es) 2018-06-27
CA2994428A1 (en) 2017-03-02
TN2018000058A1 (en) 2019-07-08
ECSP18014798A (es) 2018-04-30
CO2018002033A2 (es) 2018-05-21
DK3341379T3 (da) 2019-12-02
ME03650B (me) 2020-07-20
ES2756603T3 (es) 2020-04-27
CR20180104A (es) 2018-04-24
HRP20192101T1 (hr) 2020-02-21
TW201718598A (zh) 2017-06-01
WO2017035060A1 (en) 2017-03-02
SI3341379T1 (sl) 2019-11-29
MD3341379T2 (ro) 2020-01-31
IL257061A (en) 2018-03-29
CN107922434B (zh) 2020-06-19
KR20180030704A (ko) 2018-03-23
PL3341379T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
DOP2018000058A (es) Inhibidores de ezh2
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CO2017011183A2 (es) Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017011484A2 (es) Inhibidores de bromodominio
CO2018004750A2 (es) Composiciones para inhibir la actividad arginasa
PH12015502028A1 (en) Ido inhibitors
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
NI201600056A (es) Inhibidores de bromodominio
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
EA201890052A1 (ru) Регуляторы nrf2
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
CR20180560A (es) Ésteres de oxaboral y sus usos